Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable (Details Narrative)

v3.25.4
Accounts Payable (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
May 31, 2025
Feb. 26, 2025
Defined Benefit Plan Disclosure [Line Items]          
Issuance of pre-funded warrants       24,390  
Exercise price       $ 2.46 $ 2.8375
Issuance of common stock in settlement of vendor payable     $ 810,000    
Warrants outstanding       $ 44,000  
Stock issuance   $ 1,100,000      
Advisory Agreement [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Cash payment $ 100,000        
Warrants outstanding 150,000        
Stock issuance $ 537,000        
Related party transaction description The Agreement began on July 1, 2025, and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the Company’s common stock.        
Cytovance Biologics Inc [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Issuance of pre-funded warrants   326,251      
Exercise price   $ 0.0001      
Payments in pre-funded warrants, at fair value   $ 847,000    
Issuance of common stock in settlement of vendor payable     $ 810,000    
Legal Services Firm [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Prior year unpaid fees   $ 1,000,000